NASDAQ:FENC Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free FENC Stock Alerts $11.12 +0.03 (+0.27%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$11.04▼$11.3750-Day Range$8.82▼$11.1252-Week Range$6.30▼$11.92Volume120,083 shsAverage Volume106,949 shsMarket Capitalization$300.68 millionP/E RatioN/ADividend YieldN/APrice Target$16.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Fennec Pharmaceuticals alerts: Email Address Fennec Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside50.6% Upside$16.75 Price TargetShort InterestBearish8.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 25 Articles This WeekInsider TradingSelling Shares$378,742 Sold Last QuarterProj. Earnings Growth407.69%From $0.13 to $0.66 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.76 out of 5 starsMedical Sector481st out of 938 stocksBiological Products, Except Diagnostic Industry74th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.75, Fennec Pharmaceuticals has a forecasted upside of 50.6% from its current price of $11.12.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.50% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 14.4, which indicates bearish sentiment.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently decreased by 1.17%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FENC. Previous Next 2.2 News and Social Media Coverage News SentimentFennec Pharmaceuticals has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Fennec Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows4 people have added Fennec Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $378,742.00 in company stock.Percentage Held by Insiders11.25% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to grow by 407.69% in the coming year, from $0.13 to $0.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is -18.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is -18.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Fennec Pharmaceuticals Stock (NASDAQ:FENC)Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More FENC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FENC Stock News HeadlinesMarch 28, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $23,190.58 in StockMarch 26, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) CFO Sells $153,725.00 in StockMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 27, 2024 | finance.yahoo.comChief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC)March 26, 2024 | finance.yahoo.comChief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC)March 25, 2024 | americanbankingnews.comEquities Analysts Offer Predictions for Fennec Pharmaceuticals Inc's FY2028 Earnings (NASDAQ:FENC)March 25, 2024 | americanbankingnews.comWedbush Weighs in on Fennec Pharmaceuticals Inc's Q1 2024 Earnings (NASDAQ:FENC)March 23, 2024 | americanbankingnews.comWedbush Comments on Fennec Pharmaceuticals Inc's Q3 2024 Earnings (NASDAQ:FENC)March 28, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 22, 2024 | markets.businessinsider.comBuy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion PotentialMarch 22, 2024 | finance.yahoo.comQ4 2023 Fennec Pharmaceuticals Inc Earnings CallMarch 21, 2024 | investorplace.comFENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023March 21, 2024 | globenewswire.comFennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | americanbankingnews.comFY2024 EPS Estimates for Fennec Pharmaceuticals Inc Lowered by Analyst (NASDAQ:FENC)March 20, 2024 | americanbankingnews.comFennec Pharmaceuticals Inc to Post Q2 2024 Earnings of $0.09 Per Share, Wedbush Forecasts (NASDAQ:FENC)March 19, 2024 | bizjournals.comRTP firm inks licensing deal for European drug launchMarch 19, 2024 | globenewswire.comFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024March 19, 2024 | americanbankingnews.comFennec Pharmaceuticals (NASDAQ:FENC) Price Target Raised to $18.00 at Craig HallumMarch 19, 2024 | americanbankingnews.comFennec Pharmaceuticals (NASDAQ:FENC) Receives "Outperform" Rating from WedbushMarch 17, 2024 | globenewswire.comFennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New ZealandMarch 16, 2024 | finance.yahoo.comFENC Apr 2024 12.500 callMarch 14, 2024 | msn.comNearly 1,000 Family Dollar stores are closing, owner Dollar Tree announcesMarch 13, 2024 | nz.finance.yahoo.com'Milli Vanilli' Review: A Captivating and Moving DocumentaryMarch 13, 2024 | finance.yahoo.comAnalysts Are Optimistic We'll See A Profit From Fennec Pharmaceuticals Inc. (NASDAQ:FENC)March 6, 2024 | seekingalpha.comFennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock PriceMarch 1, 2024 | markets.businessinsider.comBuy Rating for Fennec Pharmaceuticals Amid Strong Pedmark Sales and Market Expansion PotentialFebruary 29, 2024 | finanznachrichten.deFennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 ResultsSee More Headlines Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$16.75 High Stock Price Target$18.00 Low Stock Price Target$16.00 Potential Upside/Downside+50.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E Ratio85.54 P/E GrowthN/ANet Income$-16,050,000.00 Net Margins-75.50% Pretax Margin-175.57% Return on EquityN/A Return on Assets-79.84% Debt Debt-to-Equity RatioN/A Current Ratio4.84 Quick Ratio4.39 Sales & Book Value Annual Sales$21.25 million Price / Sales14.15 Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-111.20Miscellaneous Outstanding Shares27,040,000Free Float23,998,000Market Cap$300.68 million OptionableOptionable Beta0.35 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Rostislav Raykov (Age 42)Pres, CEO & Director Mr. Robert C. Andrade (Age 43)Chief Financial Officer Mr. Mark GowlandControllerMr. Lei FangPres of Pharstat IncMs. Anne McKay (Age 64)Regulatory Consultant Key CompetitorsAdverum BiotechnologiesNASDAQ:ADVMAura BiosciencesNASDAQ:AURAPoseida TherapeuticsNASDAQ:PSTXBlack Diamond TherapeuticsNASDAQ:BDTXSOPHiA GENETICSNASDAQ:SOPHView All CompetitorsInsiders & InstitutionsChris A RallisSold 2,114 sharesTotal: $23,190.58 ($10.97/share)Robert AndradeSold 13,975 sharesTotal: $153,725.00 ($11.00/share)Vanguard Group Inc.Bought 1,058,295 shares on 3/11/2024Ownership: 4.216%Goldman Sachs Group Inc.Bought 13,664 shares on 3/1/2024Ownership: 0.115%Gendell Jeffrey LSold 3,514 shares on 2/15/2024Ownership: 1.045%View All Insider TransactionsView All Institutional Transactions FENC Stock Analysis - Frequently Asked Questions Should I buy or sell Fennec Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares. View FENC analyst ratings or view top-rated stocks. What is Fennec Pharmaceuticals' stock price target for 2024? 4 Wall Street research analysts have issued 12-month target prices for Fennec Pharmaceuticals' stock. Their FENC share price targets range from $16.00 to $18.00. On average, they expect the company's share price to reach $16.75 in the next year. This suggests a possible upside of 50.6% from the stock's current price. View analysts price targets for FENC or view top-rated stocks among Wall Street analysts. How have FENC shares performed in 2024? Fennec Pharmaceuticals' stock was trading at $11.22 at the beginning of the year. Since then, FENC shares have decreased by 0.9% and is now trading at $11.12. View the best growth stocks for 2024 here. When is Fennec Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FENC earnings forecast. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its quarterly earnings results on Monday, November, 6th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. The business had revenue of $6.52 million for the quarter, compared to analyst estimates of $5.22 million. During the same period last year, the business posted ($0.31) EPS. What guidance has Fennec Pharmaceuticals issued on next quarter's earnings? Fennec Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $20.7 million-$21.2 million, compared to the consensus revenue estimate of $19.6 million. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL). Who are Fennec Pharmaceuticals' major shareholders? Fennec Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.22%), Vanguard Group Inc. (4.22%), DG Capital Management LLC (3.98%), AIGH Capital Management LLC (1.22%), Gendell Jeffrey L (1.04%) and Worth Venture Partners LLC (0.52%). Insiders that own company stock include Chris A Rallis, Robert Andrade and Rosty Raykov. View institutional ownership trends. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FENC) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.